Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CTAD 2023 | Exploring the impact of CT1812 on EEG biomarkers in Alzheimer’s disease: a pilot study

Willem de Haan, PhD, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands, speaks on a 4-week pilot study examining the impact of CT1812 on electroencephalogram (EEG) markers of Alzheimer’s disease (AD). CT1812 is an antagonist of the sigma2 receptor, which interferes with Aβ-induced synaptic toxicity as a potential treatment for AD. The compound successfully reversed alpha-to-theta EEG oscillation slowing characteristic of AD. This was predominant in central regions but followed the same pattern across the entirety of the cortex. Additionally, the compound improved functional connectivity measures, suggesting promise for CT1812 in improving AD-related EEG markers. This interview took place at the CTAD 2023 conference in Boston, MA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Willem de Haan reports the following disclosures: Our EEG lab performs EEG analysis in pharmaceutical trials by Cognition Therapeutics, Vivoryon, Immunobrain, Treeway and CervoMed (for which I do not receive personal compensation).